This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).
Males or females 18 - 70 years of age inclusive at the time of consent.
Diagnosis of AATD and homozygous for the PiZZ mutation (confirmed by genetic testing).
Blood total AAT level <11 μM or equivalent protein in mg/dL.
Patients receiving augmentation therapy in regions where augmentation is not SoC must be willing to washout augmentation therapy for at least 6 weeks prior to signing the ICF and for the length of the study (unless clinically indicated)
Body mass index >30
Lung or liver transplant or on waiting list for lung or liver transplant or status post lung volume reduction surgery.
Clinical evidence of severe bronchiectasis as per the discretion of the investigator (eg, excessive sputum production or recurrent infections requiring antibiotic use [>4x/year]).
FibroScan liver stiffness measurement ≥7.5 kilopascals (kPa). (For sites without access to FibroScan, APRI >0.5 can be used as a surrogate exclusion criterion [Yilmaz, 2011].
Single group
BEAM-302
DrugBEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
Phase 1 Dose Exploration: Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Numbers and percentages of patients reporting a given AE
Phase 2 Dose Expansion: Absolute blood levels of total AAT
Absolute Levels of AAT over time
Phase 1 Dose Exploration: Absolute blood levels of total AAT
Absolute Levels of AAT over time
Phase 2 Dose Expansion: Rates of TEAEs and SAEs
Numbers and percentages of patients reporting a given AE
Click on the lead sponsor to view all of their trials.
